Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
PaperCitations, authors & open-access status
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 846 citations, 2015 year and green oa status.
846
Citations
2015
Year
green
OA Status